Moderna Peers Into Post-Pandemic Future For Respiratory Vaccines

Moderna, Inc. has laid out clear plans for how it intends to become a significant player in the market for vaccines against respiratory diseases – COVID-19, respiratory syncytial virus (RSV) and influenza – over the next several years, first with vaccines against each individual disease and subsequently with combination products.

During a vaccines R&D day on 11 April, the firm offered updates on the vaccine development efforts that are a part of its overall long-term development and commercial strategy as the COVID-19 pandemic transitions to an endemic phase and sales of its